Trial
NCT03600818
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
Condition
Polymyalgia Rheumatica
Intervention
Sarilumab SAR153191 (REGN88)
Why stopped
Protracted recruitment timeline exacerbated by COVID-19 pandemic
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-10